



Confirmation No.: 9150

Appl. No : 10/657,211
Applicant : Terry E. Thomas and Emer Clarke
Filed : September 9, 2003
Title : Novel Antibody Compositions For Preparing Enriched
Mesenchymal Progenitor Preparations
TC./A.U. : 1645
Examiner : Unknown

Docket No. : 7771-104
Customer No. : 001059

Honorable Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of publications of which Applicant is aware. Pursuant to 37 CFR 1.98(d) Applicant is not required to submit the references listed on the Information Disclosure Statement as all of the references were previously submitted by Applicant or were cited by the Examiner in the parent application U.S. Patent Application No. 09/864,884 filed May 25, 2001. However, Applicant is enclosing a copy of each of the two new references, Erices et al. (2000) and Reyes et al. (2001).

All of the publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.


The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,


BERESKIN & PARR

By 
Micheline Gravelle
Reg. No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2
Tel: 416-957-1682
Fax: 416-361-1398

Attachments

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/657,211
Filing Date	September 9, 2003
First Named Inventor	Terry E. Thomas
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	7771-104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Allay, J.A. et al., Human Gene Therapy. 8:1417-1427 (1997).	
		Bruder, S.P. et al., J. Cell. Biochem.. 64:278-294 (1997).	
		Majumdar, M.K. et al., J. Cell. Physiol. 176:57-66 (1998).	
		Pittenger, M.F., et al. Science. 284:143-147 (1999)	
		Reyes, M. et al. Blood 92:725a (1998).	
		Erices et al. British Journal of Haematology 109, 235-242 (2000)	
		Reyes et al. Blood Vol. 98, No. 9, 2615-2625 (2001)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.